EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comprehensive genomic profiling and therapeutic implications for Taiwanese patients with treatment‐naïve breast cancer

Shang-Hung Chen iD, Ka-Po Tse, Yen-Jung Lu, Shu-Jen Chen, Yu-Feng Tian, Kien Thiam Tan, Chien-Feng Li

Cancer Medicine · 2024

DOI: 10.1002/cam4.7384 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Shang-Hung Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan. Hauptthemen laut MEDLINE: Breast Neoplasms, Mutation, Biomarkers, Tumor. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Breast cancer is a heterogeneous disease categorized based on molecular characteristics, including hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) expression levels. The emergence of profiling technology has revealed multiple driver genomic alterations within each breast cancer subtype, serving as biomarkers to predict treatment outcomes. This study aimed to explore the genomic landscape of breast cancer in the Taiwanese population through comprehensive genomic profiling (CGP) and identify diagnostic and predictive biomarkers.

Methods

Targeted next‐generation sequencing‐based CGP was performed on 116 archived Taiwanese breast cancer specimens, assessing genomic alterations (GAs), including single nucleotide variants, copy number variants, fusion genes, tumor mutation burden (TMB), and microsatellite instability (MSI) status. Predictive variants for FDA‐approved therapies were evaluated within each subtype.

Results

In the cohort, frequent mutations included PIK3CA (39.7%), TP53 (36.2%), KMT2C (9.5%), GATA3 (8.6%), and SF3B1 (6.9%). All subtypes had low TMB, with no MSI‐H tumors. Among HR + HER2− patients, 42% (27/65) harbored activating PIK3CA mutations, implying potential sensitivity to PI3K inhibitors and resistance to endocrine therapies. HR + HER2− patients exhibited intrinsic hormonal resistance via FGFR1 gene gain/amplification (15%), exclusive of PI3K/AKT pathway alterations. Aberrations in the PI3K/AKT/mTOR and FGFR pathways were implicated in chemoresistance, with a 52.9% involvement in triple‐negative breast cancer. In HER2+ tumors, 50% harbored GAs potentially conferring resistance to anti‐HER2 therapies, including PIK3CA mutations (32%), MAP3K1 (2.9%), NF1 (2.9%), and copy number gain/amplification of FGFR1 (18%), FGFR3 (2.9%), EGFR (2.9%), and AKT2 (2.9%).

Conclusion

This study presents CGP findings for treatment‐naïve Taiwanese breast cancer, emphasizing its value in routine breast cancer management, disease classification, and treatment selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsMutationBiomarkers, TumorHumansFemaleTaiwanMiddle AgedAdultAgedHigh-Throughput Nucleotide SequencingDNA Copy Number VariationsGenomicsClass I Phosphatidylinositol 3-KinasesMicrosatellite InstabilityErb-b2 Receptor Tyrosine KinasesGene Expression Profiling

Stichwörter der Autor:innen

breast cancercomprehensive genomic profilingnext‐generation sequencingprecision medicine

Substanzen

Biomarkers, TumorClass I Phosphatidylinositol 3-KinasesErb-b2 Receptor Tyrosine KinasesPIK3CA protein, human

Autor:innen und Institutionen

  • National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan.
  • Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • ACT Genomics, Co. Ltd., Taipei, Taiwan.
  • Division of Colorectal Surgery, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan.
  • Department of Health and Nutrition, Chia-Nan University of Pharmacy and Science, Tainan, Taiwan.
  • Anbogen Therapeutics, Inc., Taipei, Taiwan.

ORCID-Profile: Shang-Hung Chen

Förderung

  • Ministry of Health and Welfare

Zitieren

APA

Chen, S. H., Tse, K. P., Lu, Y. J., Chen, S. J., Tian, Y. F., Tan, K. T., & Li, C. F. (2024). Comprehensive genomic profiling and therapeutic implications for Taiwanese patients with treatment‐naïve breast cancer. Cancer Medicine. https://doi.org/10.1002/cam4.7384

Vancouver

Chen SH, Tse KP, Lu YJ, Chen SJ, Tian YF, Tan KT, et al. Comprehensive genomic profiling and therapeutic implications for Taiwanese patients with treatment‐naïve breast cancer. Cancer Medicine. 2024. doi:10.1002/cam4.7384

BibTeX
@article{Chen2024,
  author = {Chen, Shang-Hung and Tse, Ka-Po and Lu, Yen-Jung and Chen, Shu-Jen and Tian, Yu-Feng and Tan, Kien Thiam and Li, Chien-Feng},
  title = {Comprehensive genomic profiling and therapeutic implications for Taiwanese patients with treatment‐naïve breast cancer},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.7384}
}
Kostenlos starten →